Share ownership Roche Holding AG

ROP

CH1499059983

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 09:01:24 15/07/2026 pm IST			5-day change	1st Jan Change
330.20 ^CHF	+0.98%		-1.40%	+0.61%

03:27pm	Berenberg Downgrades Qiagen Rating, Price Target Amid Rising Competition, Growth Concerns	MT
11:10am	Roche's Gazyva/Gazyvaro Lands Priority Review From US FDA in Nephropathy	MT

Share class: Roche Holding AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,66,91,000	2,95,39,418 ( 27.69 %)	0	88.78 %
Stock B	1	70,25,62,700	68,89,23,187 ( 98.06 %)	1,36,36,063 ( 1.941 %)

Major shareholders: Roche Holding AG

Name	Stocks	%	Valuation
Sjunde AP-fonden 0.1602 %	11,25,554	0.1602 %	464 M CHF
DWS CH AG 0.1132 %	7,95,479	0.1132 %	328 M CHF
Baloise Asset Management AG 0.1081 %	7,59,195	0.1081 %	313 M CHF
Capfi Delen Asset Management NV 0.0933 %	6,55,387	0.0933 %	270 M CHF
State Street Global Advisors Ltd. 0.0879 %	6,17,327	0.0879 %	255 M CHF
Berner Kantonalbank AG (Investment Management) 0.0857 %	6,02,295	0.0857 %	248 M CHF
Basellandschaftliche Kantonalbank (Investment Management) 0.0787 %	5,53,237	0.0787 %	228 M CHF
LLB Asset Management AG 0.0707 %	4,96,427	0.0707 %	205 M CHF
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 0.0686 %	4,81,746	0.0686 %	199 M CHF
LUKB Expert Fondsleitung AG 0.0667 %	4,68,912	0.0667 %	193 M CHF
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Aristotle Capital Management LLC 0.0367 %	20,63,885	0.0367 %	106 M CHF
Saratoga Research & Investment Management 0.023 %	12,91,630	0.023 %	66 M CHF
Boston Common Asset Management LLC 0.005735 %	3,22,354	0.005735 %	17 M CHF
Old National Bank (Investment Management) 0.004588 %	2,57,854	0.004588 %	13 M CHF
Hantz Financial Services, Inc. 0.003829 %	2,15,187	0.003829 %	11 M CHF
Altrius Capital Management, Inc. 0.003148 %	1,76,959	0.003148 %	9 M CHF
S & Co., Inc. 0.002501 %	1,40,551	0.002501 %	7 M CHF
Bard Financial Services, Inc. 0.002467 %	1,38,650	0.002467 %	7 M CHF
AEGON Investment Management BV 0.002318 %	1,30,284	0.002318 %	7 M CHF
The Huntington National Bank (Columbus, Ohio) 0.002188 %	1,22,990	0.002188 %	6 M CHF
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Hoffmann Family 64.46 %	6,87,70,980	64.46 %	28 919 M CHF
Melchior Oeri 3.792 %	40,45,950	3.792 %	1 701 M CHF
Maja Oeri 3.792 %	40,45,950	3.792 %	1 701 M CHF
Severin Schwan 0.2493 %	2,65,962	0.2493 %	112 M CHF
zCapital AG 0.089 %	95,000	0.089 %	40 M CHF
Mirabaud Asset Management (Suisse) SA 0.0614 %	65,500	0.0614 %	28 M CHF
GAM Investment Management (Switzerland) AG 0.0535 %	57,122	0.0535 %	24 M CHF
Carne Global Fund Managers (Ireland) Ltd. 0.0469 %	50,059	0.0469 %	21 M CHF
Valiant Bank AG 0.0452 %	48,202	0.0452 %	20 M CHF
Sjunde AP-fonden 0.0435 %	46,432	0.0435 %	20 M CHF
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	10.98%
Institutional	4.57%
Others	0.02%
Unknown	84.43%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	10.98%
Switzerland	1.33%
United States	0.95%
United Kingdom	0.42%
Sweden	0.24%
Germany	0.22%
Spain	0.16%
France	0.13%
Ireland	0.13%
Belgium	0.11%
Netherlands	0.1%
Liechtenstein	0.1%
Canada	0.08%
Finland	0.07%
Italy	0.07%
Taiwan	0.06%
New Zealand	0.06%
Luxembourg	0.06%
Norway	0.05%
Austria	0.05%
Portugal	0.04%
Denmark	0.03%
South Africa	0.03%
Japan	0.02%
Singapore	0.02%
Australia	0.02%
Hong Kong	0.01%

Based on 1000 largest holdings

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

1,03,249

Sector

Pharmaceuticals

Calendar

23/07 - Earnings release - Q2 2026

More about the company